Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

BIOSPECIFICS TECHNOLOGIES CORP

Form 4 July 26, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Wegman Thomas Issuer Symbol **BIOSPECIFICS TECHNOLOGIES** (Check all applicable) CORP [BSTC.PK] (Last) (First) (Middle) 3. Date of Earliest Transaction _X__ Director _X__ 10% Owner X_ Officer (give title __ Other (specify (Month/Day/Year) below) 1764 BRIAR PLACE 07/13/2007 President (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting MERRICK, NY 11566 Person

| (City) | (State) | (Zip) Tab | le I - Non-l | Derivative Sec | urities | Acqui | red, Disposed of | , or Beneficial | ly Owned |
|--|--------------------------------------|---|--|--|---------|--------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactic Code (Instr. 8) | 4. Securities Approx Disposed of (Instr. 3, 4 and Amount | of (D) | ed (A) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock, \$0.001 par value | 07/13/2007 | | W | 2,048,442 (1) | A | \$0 | 2,098,386 | I | Held by the Estate of Edwin H. Wegman |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Expiration Date Expiration Date Expiration Date Expiration Date (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | 7. Title and Amount Underlying Securitie (Instr. 3 and 4) | | |
|---|---|--------------------------------------|---|---|--|---------------------|---|--|-------------------------|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amous Numb Shares |
| Stock Option (Right to Buy) | \$ 1 | 07/13/2007 | | W | 39,000 (2) | 09/30/2003 | 08/16/2007(3) | Common Stock, \$0.001 par value | 39,0 |
| Stock Option (Right to Buy) | \$ 1.1 | 07/13/2007 | | W | 100,000 | 01/23/2006 | 08/16/2007(3) | Common Stock, \$0.001 par value | 100,0 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--------------------------------|---------------|-----------|-----------|-------|--|--|--|
| r g | Director | 10% Owner | Officer | Other | | | |
| Wegman Thomas | | | | | | | |
| 1764 BRIAR PLACE | X | X | President | | | | |
| MERRICK, NY 11566 | | | | | | | |

Signatures

/s/ Thomas L.
Wegman

**Signature of Reporting
Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On July 13, 2007, the Reporting Person was named as a co-executor of the estate of his father, Edwin H. Wegman. The Estate of Edwin H. Wegman owns beneficially more than 10% of the Issuer's outstanding capital stock (2,048,442 shares of the Issuer's common stock) which consists of (i) 1,843,327 shares of the Issuer held in the name of The S.J. Wegman Company, and (ii) 205,115 shares of the Issuer which are held directly by the Estate of Edwin H. Wegman. 1,843,327 of the shares in the Estate of Edwin H. Wegman held in the name of The S. J. Wegman Company are pledged to the Issuer with voting and dispositive power granted to the board of directors of the Issuer. The Reporting Person is also a residual beneficiary of the Estate of Edwin H. Wegman.

(2) The Estate of Edwin H. Wegman also beneficially owns options to purchase 139,000 shares of the Issuer's common stock.

(3)

Reporting Owners 2

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

Under the Issuer's 2001 Employee Stock Option Plan, the Estate of Edwin H. Wegman must exercise all of its options by midnight, August 16, 2007 because all options expire 6 months from the death of the option holder.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.